Curbside Consultation in Retina : (Record no. 5378)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 07596nam a22004693i 4500 |
001 - CONTROL NUMBER | |
control field | EBC5526246 |
003 - CONTROL NUMBER IDENTIFIER | |
control field | MiAaPQ |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20240724113359.0 |
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
fixed length control field | m o d | |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | cr cnu|||||||| |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 240724s2018 xx o ||||0 eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
International Standard Book Number | 9781040140550 |
Qualifying information | (electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
Canceled/invalid ISBN | 9781630914509 |
035 ## - SYSTEM CONTROL NUMBER | |
System control number | (MiAaPQ)EBC5526246 |
035 ## - SYSTEM CONTROL NUMBER | |
System control number | (Au-PeEL)EBL5526246 |
035 ## - SYSTEM CONTROL NUMBER | |
System control number | (OCoLC)1056072454 |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | MiAaPQ |
Language of cataloging | eng |
Description conventions | rda |
-- | pn |
Transcribing agency | MiAaPQ |
Modifying agency | MiAaPQ |
050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
Classification number | RE551 .C873 2019 |
082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
Classification number | 617.7/35 |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Fekrat, Sharon. |
245 10 - TITLE STATEMENT | |
Title | Curbside Consultation in Retina : |
Remainder of title | 49 Clinical Questions. |
250 ## - EDITION STATEMENT | |
Edition statement | 2nd ed. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Place of production, publication, distribution, manufacture | Milton : |
Name of producer, publisher, distributor, manufacturer | Taylor & Francis Group, |
Date of production, publication, distribution, manufacture, or copyright notice | 2018. |
264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Date of production, publication, distribution, manufacture, or copyright notice | ©2018. |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 1 online resource (298 pages) |
336 ## - CONTENT TYPE | |
Content type term | text |
Content type code | txt |
Source | rdacontent |
337 ## - MEDIA TYPE | |
Media type term | computer |
Media type code | c |
Source | rdamedia |
338 ## - CARRIER TYPE | |
Carrier type term | online resource |
Carrier type code | cr |
Source | rdacarrier |
490 1# - SERIES STATEMENT | |
Series statement | Curbside Consultation in Ophthalmology Series |
505 0# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Cover -- Half Page -- Title Page -- Copyright Page -- Dedication -- Table of Contents -- Acknowledgments -- About the Editor -- About the Associate Editors -- Contributing Authors -- Preface -- Foreword -- Introduction -- Question 1 What Is Hemorrhagic Occlusive Retinal Vasculitis, and Why Do I Need to Know About It? -- Question 2 How Do I Counsel My Patients With Dry Age-Related Macular Degeneration and What About Various Vitamin Supplements? -- Question 3 What Are the Age-Related Macular Degeneration Look-Alikes? Do I Treat Them Any Differently? -- Question 4 How Long Are We Going to Have to Keep Doing Frequent Intravitreal Injections Any Other Options Anytime Soon? What Are We Waiting For? -- Question 5 Anything Coming Down the Pike yet for Dry Age-Related Macular Degeneration? -- Question 6 Are We Ever Going to Use Stem Cells? For What? What's the Scoop? -- Question 7 What Is the Easiest Way to Do a Good B-Scan? -- Question 8 When Do I Refer a Patient With a Branch Retinal Artery Occlusion or Central Retinal Artery Occlusion, What Is the Work-Up, and What Are the Treatment Options? -- Question 9 What Do I Do When I See a Branch Retinal Vein Occlusion? -- Question 10 When Do I Refer a Patient With a Central Retinal Vein Occlusion, What Is the Work-Up, and What Are the Treatment Options? -- Question 11 What Visualization Agents Are Used During Vitrectomy Surgery? And Wait, Tell Me About the Intraocular Tamponade Options! -- Question 12 What Type of Intraocular Lens Should Be Considered in an Eye With Vitreoretinal Disease? -- Question 13 I Just Can't Keep Up With All of the Clinical Trial Acronyms. Can You Tell Me What Study Each Refers To? -- Question 14 How Do I Figure Out Whether or Not My Patient Has a Posterior Vitreous Detachment? Does There Have to Be a Weiss Ring to Make the Diagnosis?. |
505 8# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Question 15 How Soon Should a Patient With Floaters Be Examined and How Should I Manage a Patient With an Acute Posterior Vitreous Detachment? -- Question 16 How Do I Differentiate All of Those White Dot Syndromes? -- Question 17 How Do I Work Up and Manage a Patient With a White-Centered Retinal Hemorrhage? -- Question 18 How Do I Manage a Suprachoroidal Hemorrhage? -- Question 19 When Should I Suspect Endophthalmitis in My Postoperative Cataract Patient and What Are the Treatment Options? -- Question 20 How Do I Follow a Patient With a Presumed Choroidal Nevus? -- Question 21 How Do I Distinguish One Pigmented Lesion From Another? -- Question 22 How Do I Work Up and Manage a Patient With a Vitreous Hemorrhage? -- Question 23 What Is Fundus Autofluorescence? Do I Need to Add It to My Imaging Options? -- Question 24 What Additional Information Can I Get From Ultra-Widefield Fluorescein Angiography That I Can't Get From a 30-Degree Angiogram? -- Question 25 What Imaging Options Are There to Detect an Intraocular Foreign Body? When Do I Get Which One? -- Question 26 Why Would I Want to Look at Choroidal Thickness on Optical Coherence Tomography? -- Question 27 When Should I Refer a Patient With an Epiretinal Membrane and What if There Is Associated Cystoid Macular Edema? -- Question 28 How Do I Differentiate a Macular Hole From a Lamellar Hole From an Epiretinal Membrane With a Pseudohole, and Why Do I Care? -- Question 29 What Is Micropulse Laser and What Can It Be Used For? -- Question 30 What Is The Treatment Paradigm for Postoperative Pseudophakic Macular Edema? -- Question 31 What Is Dyeless Angiography (Optical Coherence Tomography Angiography) And What Do I Need To Know About It? Will It Replace Fluorescein Angiography? -- Question 32 Central Serous? What Now? Management Options for Central Serous Retinopathy. |
505 8# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Question 33 What Systemic Medications Require Periodic Fundus Evaluation? What Am I Looking for and What Tests Do I Do? -- Question 34 Should I Send a Patient With a Large Chronic Macular Hole to a Retina Doctor? Do They Even Operate on Those? -- Question 35 Explain All of These New Anticoagulants to Me. Should I Consider Stopping Them Preoperatively? -- Question 36 When Should Cataract Surgery Be Performed if a Vitrectomy Is Planned-Before, During, or After? -- Question 37 What Should I Tell a Patient With Retinitis Pigmentosa About Prognosis and Should I Prescribe Vitamin A or Other Supplements? -- Question 38 Why Should I Send My Retinal Degeneration Patients to Specialists if There Is No Cure for Their Condition? -- Question 39 What Is the Artificial Retinal Prosthesis (Argus II Implant) and Who Would Be a Good Candidate for It? -- Question 40 How Do You Differentiate Between Retinoschisis and Retinal Detachment? -- Question 41 What Systemic Conditions Are Associated With an Increased Risk of Retinal Detachment? What Should I Do About It? -- Question 42 What Retinal Findings Should Be Treated Before Cataract Surgery, Refractive Surgery, or Yttrium-Aluminum-Garnet Laser? -- Question 43 Do Chronic Rhegmatogenous Retinal Detachments Need Surgical Repair? -- Question 44 Should I Use Jetrea or a Gas Bubble or Just Do a Vitrectomy for Vitreomacular Traction? -- Question 45 When Should a Patient With Diabetic Retinopathy Be Considered for a Vitrectomy? -- Question 46 How Do I Follow a Patient Who Has Diabetes and Becomes Pregnant? What Tests Can I Do? -- Question 47 How Long Should I Wait to Perform Cataract Surgery After Treatment of Diabetic Macular Edema or Retinopathy? -- Question 48 I Saw Some Retinal Neovascularization but My Patient Does Not Have Diabetes, so What Else Can It Be?. |
505 8# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Question 49 When Should I Consider Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity? -- Financial Disclosures -- Index. |
520 ## - SUMMARY, ETC. | |
Summary, etc. | Curbside Consultation in Retina: 49 Clinical Questions, Second Edition contains new questions and brief, practical, and evidence-based answers to the most frequently asked questions that are posed during a "curbside consultation" between surgical colleagues. |
588 ## - SOURCE OF DESCRIPTION NOTE | |
Source of description note | Description based on publisher supplied metadata and other sources. |
590 ## - LOCAL NOTE (RLIN) | |
Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
655 #4 - INDEX TERM--GENRE/FORM | |
Genre/form data or focus term | Electronic books. |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
Relationship information | Print version: |
Main entry heading | Fekrat, Sharon |
Title | Curbside Consultation in Retina |
Place, publisher, and date of publication | Milton : Taylor & Francis Group,c2018 |
International Standard Book Number | 9781630914509 |
797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
Uniform title | Curbside Consultation in Ophthalmology Series |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5526246">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5526246</a> |
Public note | Click to View |
No items available.